|Bid||20.72 x 800|
|Ask||23.75 x 1800|
|Day's Range||22.16 - 23.11|
|52 Week Range||17.80 - 38.77|
|Beta (3Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer (BC11Ae) and one targeting the beta-globin locus, for the treatment of sickle cell disease and beta-thalassemia. The Company reported the data at the 24th Congress of the European Hematology Association in Amsterdam.
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
With an upcoming phase 1/2 trial, new medicines in development, and new strategic collaborations, the gene-editing leader is framing an exciting year.
Editas (EDIT) delivered earnings and revenue surprises of -5.26% and -73.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587).
A new gene editing company founded by two Harvard scientists and one of the men behind Editas Medicine has launched with nearly $59 million to develop a single treatment for the leading cause of death worldwide.
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Editas Medicine, Inc. (NASDAQ:EDIT) shar...
Is Editas Medicine, Inc. (NASDAQ:EDIT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
CAMBRIDGE, Mass., April 30, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.